One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMS
Fondazione IRCCS Policlinico San Matteo di Pavia
100 participants
Nov 28, 2025
OBSERVATIONAL
Conditions
Summary
By detailed sequence analysis and subsequent biophysical characterization of prototypic light chains, this project aims to identify sequence fingerprints in IGLV1-44 light chains leading to AL amyloidosis and POEMS syndrome. This understanding might help improve the risk stratification and early diagnosis of patients overexpressing pathologic IGLV1-44 LCs. Moreover, the development of nanobodies efficient in recognizing and stabilizing IGLV1-44 light chains which exert direct toxicity in cardiac AL amyloidosis and POEMS syndrome might form the basis for future development of therapeutic agents capable of counteracting IGLV1-44 light chain proteotoxicity.
Eligibility
Inclusion Criteria4
- Biopsy-proven diagnosis of systemic AL amyloidosis, POEMS syndrome or multiple myeloma
- Planned peripheral blood sampling +/- bone marrow aspiration
- Age \> 18 years
- Willingness to allow use of clinical data and diagnostic leftovers of clinical specimens for research purposes through signing a written informed consent.
Exclusion Criteria4
- Undefined monoclonal gammopathy or non-AL amyloidosis
- Patients fulfilling the criteria for complete hematologic response after anti-clonal therapy
- Age \<18 years
- Failure to show willingness to allow use of clinical data and diagnostic leftovers of clinical specimens for research purposes.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07448935